Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Boston Scientific (BSX)

Tipranks - Tipranks - Wed Apr 8, 5:38AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN) and Boston Scientific (BSX).

Easter Sale - 70% Off TipRanks

Amgen (AMGN)

Citi analyst Geoff Meacham maintained a Hold rating on Amgen today and set a price target of $345.00. The company’s shares closed last Monday at $342.57, close to its 52-week high of $346.85.

According to TipRanks.com, Meacham is a 5-star analyst with an average return of 9.4% and a 56.2% success rate. Meacham covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Amylyx Pharmaceuticals Inc, and Protagonist Therapeutics. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Amgen with a $369.16 average price target, which is a 6.9% upside from current levels. In a report issued on March 30, Bernstein also maintained a Hold rating on the stock with a $335.00 price target.

See today’s best-performing stocks on TipRanks >>

Boston Scientific (BSX)

TD Cowen analyst Josh Jennings maintained a Buy rating on Boston Scientific today and set a price target of $100.00. The company’s shares closed last Monday at $62.59.

According to TipRanks.com, Jennings is a 3-star analyst with an average return of 1.2% and a 42.6% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Orchestra BioMed Holdings, and Edwards Lifesciences. ;'>

Boston Scientific has an analyst consensus of Strong Buy, with a price target consensus of $103.23, implying a 65.6% upside from current levels. In a report issued on March 30, TipRanks – PerPlexity also upgraded the stock to Buy with a $77.00 price target.

Read More on AMGN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).